MedRx Co., Ltd (TYO:4586)
Japan
· Delayed Price · Currency is JPY 66.00
+2.00 (3.13%)
Apr 24, 2025, 3:30 PM JST
MedRx Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | - | 7 | 9 | 8 | 15 | Upgrade
|
| Other Revenue | 257 | 22 | 50 | - | 100 | Upgrade
|
| Revenue | 257 | 29 | 59 | 8 | 115 | Upgrade
|
| Revenue Growth (YoY) | 786.21% | -50.85% | 637.50% | -93.04% | -31.95% | Upgrade
|
| Cost of Revenue | - | 3 | 3 | 2 | 4 | Upgrade
|
| Gross Profit | 257 | 26 | 56 | 6 | 111 | Upgrade
|
| Selling, General & Admin | 203 | 221 | 232 | 270 | 271 | Upgrade
|
| Research & Development | 846 | 737 | 921 | 794 | 967 | Upgrade
|
| Operating Expenses | 1,050 | 960 | 1,157 | 1,067 | 1,207 | Upgrade
|
| Operating Income | -793 | -934 | -1,101 | -1,061 | -1,096 | Upgrade
|
| Interest Expense | - | - | - | -1 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -1 | 11 | -3 | 1 | -3 | Upgrade
|
| Other Non Operating Income (Expenses) | 40 | -7 | -8 | -12 | -18 | Upgrade
|
| EBT Excluding Unusual Items | -754 | -930 | -1,112 | -1,073 | -1,117 | Upgrade
|
| Gain (Loss) on Sale of Investments | -68 | - | - | - | - | Upgrade
|
| Other Unusual Items | 20 | - | 2 | 15 | 11 | Upgrade
|
| Pretax Income | -802 | -930 | -1,110 | -1,058 | -1,106 | Upgrade
|
| Income Tax Expense | 4 | 2 | 1 | 1 | 8 | Upgrade
|
| Net Income | -806 | -932 | -1,111 | -1,059 | -1,114 | Upgrade
|
| Net Income to Common | -806 | -932 | -1,111 | -1,059 | -1,114 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 35 | 25 | 21 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 35 | 25 | 21 | 16 | Upgrade
|
| Shares Change (YoY) | 24.99% | 37.12% | 18.76% | 31.47% | 35.01% | Upgrade
|
| EPS (Basic) | -18.54 | -26.80 | -43.80 | -49.58 | -68.57 | Upgrade
|
| EPS (Diluted) | -18.54 | -26.80 | -43.80 | -49.58 | -68.57 | Upgrade
|
| Free Cash Flow | -803 | -913 | -1,074 | -925 | -1,024 | Upgrade
|
| Free Cash Flow Per Share | -18.47 | -26.25 | -42.34 | -43.31 | -63.03 | Upgrade
|
| Gross Margin | 100.00% | 89.66% | 94.92% | 75.00% | 96.52% | Upgrade
|
| Operating Margin | -308.56% | -3220.69% | -1866.10% | -13262.50% | -953.04% | Upgrade
|
| Profit Margin | -313.62% | -3213.79% | -1883.05% | -13237.50% | -968.70% | Upgrade
|
| Free Cash Flow Margin | -312.45% | -3148.28% | -1820.34% | -11562.50% | -890.44% | Upgrade
|
| EBITDA | -755 | -889 | -1,055 | -1,001 | -1,041 | Upgrade
|
| EBITDA Margin | -293.77% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 38 | 45 | 46 | 60 | 55 | Upgrade
|
| EBIT | -793 | -934 | -1,101 | -1,061 | -1,096 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.